MDACC Study No:2012-0504 ( NCT No: NCT01510184)
Title:A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell Lymphoma in PET- negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Principal Investigator:Jason R. Westin
Treatment Agent:Ibritumomab Tiuxetan ; Rituximab
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if Zevalin (ibritumomab
tiuxetan) and rituximab can help prevent lymphoma from coming back in patients
at least 60 years old who have already received chemotherapy for the disease,
and scans have shown that all the disease is gone. The safety of this
treatment will also be studied.

Ibritumomab tituxetan is designed to attach to lymphoma cells and destroy the
cells using a radioactive particle.

Rituximab is designed to attach to lymphoma cells, which may cause them to die.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase III
Treatment Agents:Ibritumomab Tiuxetan
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Spectrum Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jason R. Westin
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults